In a new paper appearing in the Journal of Investigative Dermatology, a leading scientific publication in the field of research on skin and connective tissue, The Hormel Institute, University of ...

If you have had a similar reaction to Pfizer's COVID-19 vaccine, email [email protected] with your storyScientists ...

Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED). The CHASE Phase 2b trial is a multicenter, randomized, double-masked, ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

rapid protein clearance rates and high cell turnover in the front of the eye have severely limited the therapeutic potential of biologics and gene therapies for the treatment of corneal epithelial ...

Five years after a Fourth of July fireworks accident blinded him, a young man has regained his eyesight thanks to a ...

Weaknesses: The central premise of the manuscript, that the spiral patterning of epithelial corneal cells occurs without guidance cues, is not fully supported. The authors overlook the potential role ...

The model is well constructed, however the central premise of the manuscript, that the spiral patterning of epithelial corneal cells occurs without guidance cues, is incomplete and not fully supported ...

Consistently, a significant increase in HDAC6 was observed in mouse corneas with bacterial keratitis. Overexpression of HDAC6 in mice results in a significant thickening of the corneal epithelium.